Showcasing the expertise of top-tier specialists who contributed to the newly released guidelines for the care of thrombosis in cancer patients, this exciting guide was written and edited by members of the American Society of Clinical Oncology panel, (ASCO), on the prevention and treatment of cancer-associated thrombosis, among others, and provides an authoritative discussion of strategies to effectively implement and interpret the new ASCO/NCCN directives. Standing as the only up-to-date source to readily examine exciting new translational science findings regarding the biology of cancer-associated thrombosis, as well as new clinical recommendations, this guide supplies an authoritative and current discussion of the mechanisms, management, and prevention of cancer-associated thrombosis. Written alongside the development of the ASCO guidelines in order to fully examine and address the entire breadth of published literature on the topic, this reference explains to specialists how to identify risk factors associated with cancer-associated thrombosis and improve patient outcomes...tracks the development and utilization of low-molecular weight heparins (LMWHs) in the prevention and treatment of cancer-associated thrombosis...contains a summary of the ASCO VTE guidelines by the Co-Chair of the ASCO Panel...offers an executive summary section in each chapter that highlights critical information...provides an at-hand overview of recent translational studies on mechanisms including the linkage of thrombosis with angiogenesis, role of tissue factor, risk assessment, screening, etiology, and emerging therapies.